← Back to Search

Hormone Therapy

Angiotensin II + Compound 21 for Preeclampsia

Phase < 1
Recruiting
Research Sponsored by Anna Stanhewicz, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18-45 years old
Be between 18 and 65 years old
Must not have
Current antihypertensive medication
Body mass index less than <18.5 or >30 kg/m2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the study visit, an average of 4 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial will help us better understand the mechanisms of blood vessel damage in women who have had preeclampsia, and how we can treat this risk of cardiovascular disease.

Who is the study for?
This trial is for women aged 18-45 who are 12 weeks to 5 years postpartum. It's specifically for those who experienced preeclampsia and those who didn't, without a history of hypertension or metabolic disease before pregnancy, skin diseases, tobacco use, or current pregnancy.
What is being tested?
The study investigates the balance of angiotensin II receptors in blood vessels after preeclampsia using intradermal microdialysis. Angiotensin II and Compound 21 are being tested to understand their effects on restoring microvascular function.
What are the potential side effects?
Potential side effects may include local reactions at the site where drugs are delivered into the skin such as redness, swelling or itching due to Angiotensin II or Compound 21. Allergic reactions could also occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 45 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking medication for high blood pressure.
Select...
My BMI is either below 18.5 or above 30.
Select...
I had high blood pressure or a metabolic disease before getting pregnant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the study visit, an average of 4 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the study visit, an average of 4 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in microvascular ang II-mediated constriction response measured by laser-Doppler flowmetry
Change in microvascular angiotensin II (ang II) type 2 receptor (AT2R)-mediated dilation response measured by laser-Doppler flowmetry

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: History of a preeclampsiaExperimental Treatment2 Interventions
Women who had preeclampsia in their most recent pregnancy
Group II: History of a healthy pregnancyExperimental Treatment2 Interventions
Women who had an uncomplicated pregnancy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Angiotensin II
2010
Completed Phase 4
~260

Find a Location

Who is running the clinical trial?

Anna Stanhewicz, PhDLead Sponsor
10 Previous Clinical Trials
392 Total Patients Enrolled
~16 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top